Simon TA, Suissa S, Skovron ML, Frisell T, Askling J, Michaud K, Pedro S, Strangfeld A, Meissner Y, Boers M, Hoffman V, Dominique A, Gomez A, Hochberg MC. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2024 Feb;64:152313. doi: 10.1016/j.semarthrit.2023.152313
Earnshaw S, Beyhaghi H, McDade C, Purser M, Marriott R, Daane L, Le Coent V, Yang J, Toback S. Clinical and economic impacts of large volume delayed sampling and pathogen reduction technology platelet processing strategies in the United States. Transfusion. 2021 Oct;61(10):2885-97. doi: 10.1111/trf.16589
Guinn NR, Guercio JR, Hopkins TJ, Grimsley A, Kurian TJ, Jimenez ML, Bolognesi MP, Schroeder R, Aronson S, Duke Perioperative Enhancement Team (POET). How do we develop and implement a preoperative anemia clinic designed to improve perioperative outcomes and reduce cost? Transfusion. 2016 Feb;56(2):297-303. doi: 10.1111/trf.13426
Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach. Semin Arthritis Rheum. 2014 Aug;44(1):39-46. doi: 10.1016/j.semarthrit.2014.03.001
Thyagarajan (Hoffman) V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients. Semin Arthritis Rheum. 2012 Dec;42(3):223-33. doi: 10.1016/j.semarthrit.2012.05.004
Wenk RE, Brewer MK, Bass G, Bishop (Johannes) K. Surveillance for post-transfusion hepatitis by a community hospital - another view. Transfusion. 1981 Sep;21:557-9. doi: 10.1046/j.1537-2995.1981.21582040819.x